Jay shared site contacts but we can circle with him for what they would like to do

Neurology Hubの皆さん

2025年のゴール設定は下記のように決まりました。

pTau217チーム：Stage 1終了

aSynチーム：pa-Syn、pa-Syn Aggの２つのアッセイの完成（臨床有用性は問わない）

TDP-43チーム：pTDP-43、TDP-43 Aggの２つのアッセイの完成（臨床有用性は問わない）

となっています。

昨年より多くの課題を科せられています。

各チーム、ゴールを満たすよう目標の設定（タイムライン）を考えてみてください。

|  |  |
| --- | --- |
| **02. Neurology Hub New Biomarker Development Project 1** | **Complete Stage 1 of the pTau217 measurement method by end of December.   -Measure clinical samples, conduct a Head-to-head comparison of the reagent's usefulness with those of Fujirebio. (>50 Dementia samples, >50 control samples) by 1Q. -Achieve the minimum conditions listed in theTPP (Performance requirements listed and tested in the TPP include: LoBDQ, Precision, Interference, Linearity, Recovery and Stability) by 4Q. -The clinical samples will be measured to evaluate the usefulness of the reagents, and the results will be reported in 4Q. (>50 Dementia samples, >50 control samples) -Begin negotiations for obtaining Ab/Ag licenses. Start preparing for patent application.** |
| **03. Neurology Hub New Biomarker Development Project 2** | **Complete Stage 1-1 of the phosphorylated alpha-Synuclein (pa-Syn) and phosphorylated alpha-Synuclein aggregate (pa-Syn Agg) measurement method by end of December. -Evaluate the usefulness of the reagent using purchased samples by 3Q. ( >30 Parkinson's samples, >30 control samples)   -Achieve the minimum conditions listed in the TPP (Performance requirements listed and tested in the TPP include: LoBDQ, Precision, Interference, Recovery and Linearity) by 3Q. -The clinical samples will be measured to evaluate the usefulness of the reagents, and the results will be reported in 4Q.( >30 Parkinson's samples, >30 control samples)** |
| **04. Neurology Hub New Biomarker Development Project 3** | **Complete Stage 1-1 of the phosphorylated TDP-43 (pTDP-43) and TDP-43 aggregate (TDP-43 Agg) measurement method by end of December. -Evaluate the usefulness of the reagent using purchased samples by 3Q. ( >20 ALS samples, >20 control samples)   -Achieve the minimum conditions listed in the TPP (Performance requirements listed and tested in the TPP include: LoBDQ, Precision, Interference, Recovery and Linearity) by 3Q. -The clinical samples will be measured to evaluate the usefulness of the reagents, and the results will be reported in 4Q.( >20 ALS samples, >20 Dementia samples, >20 control samples)** |

建部 拝